<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: <z:chebi fb="1" ids="24261">Glucocorticoids</z:chebi> potently stabilize the blood-brain barrier and ameliorate tissue <z:hpo ids='HP_0000969'>edema</z:hpo> in certain neoplastic and <z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory disorders</z:e> of the central <z:mp ids='MP_0008912'>nervous</z:mp> system, but they are largely ineffective in patients with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The reasons for this discrepancy are unresolved </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: To address the molecular basis for the paradox unresponsiveness of the blood-brain barrier during <z:mp ids='MP_0005039'>hypoxia</z:mp>, we used murine brain microvascular endothelial cells exposed to <z:chebi fb="0" ids="15379">O(2)</z:chebi>/<z:chebi fb="105" ids="17234">glucose</z:chebi> deprivation as an in vitro model </plain></SENT>
<SENT sid="3" pm="."><plain>In an in vivo approach, mice were subjected to transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> to induce <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarctions</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Blood-brain barrier damage and <z:hpo ids='HP_0000969'>edema</z:hpo> formation were chosen as surrogate markers of <z:chebi fb="1" ids="24261">glucocorticoid</z:chebi> sensitivity in the presence or absence of <z:chebi fb="0" ids="52726">proteasome inhibitors</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: <z:chebi fb="0" ids="15379">O(2)</z:chebi>/<z:chebi fb="105" ids="17234">glucose</z:chebi> deprivation reduced the expression of tight junction proteins and transendothelial resistance in murine brain microvascular endothelial cells in vitro </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="41879">Dexamethasone</z:chebi> treatment failed to reverse these effects during <z:mp ids='MP_0005039'>hypoxia</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>Proteasome-dependent degradation of the <z:chebi fb="1" ids="24261">glucocorticoid</z:chebi> receptor impaired <z:chebi fb="1" ids="24261">glucocorticoid</z:chebi> receptor transactivation thereby preventing physiological <z:chebi fb="1" ids="24261">glucocorticoid</z:chebi> activity </plain></SENT>
<SENT sid="8" pm="."><plain>Inhibition of the proteasome, however, fully restored the blood-brain barrier stabilizing properties of <z:chebi fb="1" ids="24261">glucocorticoid</z:chebi> during <z:chebi fb="0" ids="15379">O(2)</z:chebi>/<z:chebi fb="105" ids="17234">glucose</z:chebi> deprivation </plain></SENT>
<SENT sid="9" pm="."><plain>Importantly, mice treated with the <z:chebi fb="0" ids="52726">proteasome inhibitor</z:chebi> <z:chebi fb="0" ids="52717">Bortezomib</z:chebi> in combination with steroids several hours after <z:hpo ids='HP_0001297'>stroke</z:hpo> developed significantly less <z:hpo ids='HP_0002181'>brain edema</z:hpo> and functional deficits, whereas respective monotherapies were ineffective </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: We for the first time show that inhibition of the proteasome can overcome <z:chebi fb="1" ids="24261">glucocorticoid</z:chebi> resistance at the hypoxic blood-brain barrier </plain></SENT>
<SENT sid="11" pm="."><plain>Hence, combined treatment strategies may help to combat <z:hpo ids='HP_0001297'>stroke</z:hpo>-induced <z:hpo ids='HP_0002181'>brain edema</z:hpo> formation in the future and prevent secondary clinical deterioration </plain></SENT>
</text></document>